



Routine therapeutic drug monitoring (TDM) of levetiracetam is generally not helpful and is not recommended for standard dosing decisions.

Levetiracetam dosing is guided primarily by clinical response—seizure control and tolerability—rather than serum levels.[\[1\]\[2\]\[3\]](#) There is no established concentration-response relationship, and the commonly cited “therapeutic range” of 12–46 mg/L was derived from a single retrospective abstract, never validated against efficacy or toxicity.[\[1\]\[2\]](#) Multiple reviews confirm no consistent correlation between levetiracetam levels and either seizure control or adverse effects, with efficacy and toxicity observed below, within, and above the reference range.[\[4\]](#)

Why routine levels add little:

- **Predictable, linear pharmacokinetics** — high oral bioavailability (>95%), low protein binding (<10%), minimal drug-drug interactions, and a wide therapeutic window make serum concentrations largely predictable from dose.[\[4\]\[3\]](#)
- **No validated target** — the concentration that produces efficacy or toxicity varies widely between individuals, so a single value rarely changes management.[\[2\]](#)
- **“Treat the patient, not the level”** — dose titration, efficacy, and toxicity assessment are better served by clinical judgment than by a number.[\[2\]](#)

Situations where a level can be useful:

- **Assessing adherence/compliance** — an undetectable or unexpectedly low level clearly identifies nonadherence, one of the clearest indications.[\[2\]\[1\]\[5\]](#)
- **Suspected toxicity or overdose** — confirming and managing supratherapeutic exposure.[\[1\]](#)
- **Altered pharmacokinetics in special populations**, where an individualized “therapeutic concentration” (the level at which a given patient is well-controlled and tolerating therapy) can be established at baseline and followed:
- **Pregnancy** — renal clearance rises up to ~1.7-fold, levels fall progressively, and declines have been linked to increased seizures; following the ratio-to-target-concentration is reasonable.[\[3\]](#)
- **Elderly (>65 yr)** — clearance drops ~40–50%, favoring lower doses.[\[4\]\[6\]](#)



- **Children/neonates** — clearance increases 30–70%, often requiring higher weight-based doses.[\[4\]\[6\]](#)
- **Renal impairment / dialysis and critical illness** — clearance tracks with creatinine clearance; critically ill patients may have augmented clearance and be underdosed.[\[4\]\[7\]](#)
- **Enzyme-inducing antiseizure drugs** (e.g., carbamazepine) — increase levetiracetam clearance 24–60%, sometimes requiring higher doses.[\[6\]\[5\]](#)

Practical sampling note: because of the short half-life, timing matters—draw a trough before the morning dose, and separate serum from whole blood promptly, since in vitro hydrolysis can spuriously lower measured concentrations.[\[1\]](#)

In short, do not check levels routinely to guide dosing in a stable, uncomplicated patient—rely on clinical response. Reserve levels for confirming adherence, evaluating toxicity, or tracking an individualized baseline concentration in patients with altered or changing pharmacokinetics.[\[4\]\[1\]](#)

Would you like to explore how to use levetiracetam levels to guide dosing across pregnancy and postpartum?

References

1. [Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies](#). Patsalos PN, Berry DJ, Bourgeois BF, et al. *Epilepsia*. 2008;49(7):1239-76.
doi:10.1111/j.1528-1167.2008.01561.x.
2. [Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy](#). Tan J, Paquette V, Levine M, Ensom MHH. *Clinical Pharmacokinetics*. 2017;56(11):1267-1285.
doi:10.1007/s40262-017-0537-1.
3. [Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy](#). Schelhaas M, Wegner I, Edens M, et al. *Neurology*. 2023;100(2):e172-e181.
doi:10.1212/WNL.0000000000201348.
4. [Therapeutic Drug Monitoring of Levetiracetam in Select Populations](#). Jarvie D, Mahmoud SH. *Journal of Pharmacy & Pharmaceutical Sciences : A Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques*. 2018;21(1s):149s-176s.



doi:10.18433/jpps30081.

5. [Levetiracetam Therapeutic Drug Monitoring in a Large Cohort of Korean Epileptic Patients](#). Ha C, Lee HS, Joo EY, et al. Pharmaceuticals (Basel, Switzerland). 2021;14(8):826. doi:10.3390/ph14080826.
6. [Review on the Relevance of Therapeutic Drug Monitoring of Levetiracetam](#). Sourbron J, Chan H, Wammes-van der Heijden EA, et al. Seizure. 2018;62:131-135. doi:10.1016/j.seizure.2018.09.004.
7. [Levetiracetam](#). Food and Drug Administration. Updated date: 2025-07-01.